Florida Cancer Specialists & Research Institute | Strategic Alliance Partners

March 29, 2023

Panelists round out their review of staging and risk stratification in CSCC by considering how each affects the selection of optimal surgical strategies.

March 28, 2023

Martin F. Dietrich, MD, PhD, discusses how mutational profiling can inform subsequent treatment selection for patients with non–small cell lung cancer.

March 22, 2023

Following their discussions on staging and risk stratification in CSCC, key opinion leaders work to define resectability in cutaneous squamous cell carcinoma.

March 22, 2023

Expert panelists share their perspectives on best strategies to risk stratify patients diagnosed with cutaneous squamous cell carcinoma.

March 22, 2023

A television commercial produced by Florida Cancer Specialists & Research Institute, LLC has been recognized with a Silver ADDY® by the American Advertising Awards, which honors excellence in advertising as judged by creative industry professionals around the world.

March 15, 2023

A review of current staging systems used to categorize CSCC, particularly those from the American Joint Committee on Cancer and Brigham and Women's Hospital.

March 15, 2023

Opening their discussion on resectable cutaneous squamous cell carcinoma (CSCC), expert panelists elucidate its current incidence and known risk factors.

March 13, 2023

Florida Cancer Specialists & Research Institute, LLC, a consistent top performer among the 126 U.S.-based oncology practices that participated in the Center for Medicare & Medicaid Innovation Oncology Care Model, shares its results in the payment and delivery model’s final wave which ended in June 2022 in a newly released case study.

March 09, 2023

A recently published study in the New England Journal of Medicine provides further data to support that certain female patients over age 65 can achieve positive outcomes without postoperative radiation.

March 06, 2023

Drs Khushalani, Dietrich, Luke, and Patel discuss the nuances of defining resectability in cutaneous squamous cell carcinoma, the evolving treatment paradigm of resectable disease, and how to translate updated data with cemiplimab into clinical practice.

March 06, 2023

Florida Cancer Specialists & Research Institute has appointed Sachin Kamath, MD as Chairman of the FCS Executive Board Compliance Committee.

February 20, 2023

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Hitesh Patel, MD has joined its Executive Board, effective January 27, 2023.

February 20, 2023

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.

February 13, 2023

Expert oncologists look to the future of the NSCLC treatment landscape and discuss unmet needs and promising therapies.

February 13, 2023

Meghan J. Mooradian, MD, shares her approach to communicating with patients with NSCLC regarding treatment decisions based on molecular biomarkers.

February 06, 2023

Takeaways from the CheckMate 9LA, CheckMate 227, and POSEIDON trials focused on immunotherapy in non–small cell lung cancer.

February 06, 2023

Meghan J. Mooradian, MD, discusses how she makes NSCLC treatment decisions based on concurrent mutations.

January 23, 2023

Florida Cancer Specialists & Research Institute, LLC welcomes Robert Ferdman, MD to the statewide practice.

January 12, 2023

Long-serving pharmacy executive, Ray Bailey, retired on December 31, 2022.

January 09, 2023

Florida Cancer Specialists & Research Institute, LLC welcomes Board-certified medical oncologist/hematologist Madhu Unnikrishnan, MD to the statewide practice.